$STML News
Last published 6y ago
- 6y agoSTMLMenarini Group Completes Acquisition of Stemline TherapeuticsBusiness WireFLORENCE, Italy--(BUSINESS WIRE)--Menarini Group, a privately held Italian pharmaceutical and diagnostics company, today announced that is has successfully completed the acquisition of Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics (Nasdaq: STML), for an aggregate cash consideration up to $677 ...
- 6y agoTORCSTMLKLXEPTLAMoore Kuehn Encourages TORC, STML, KLXE, and PTLA Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 6y agoSTMLStemline Therapeutics Reports Fourth Quarter 2019 Financial ResultsGlobeNewswireNet revenue for ELZONRIS® was $11.8 million for the fourth quarterConference call and live webcast scheduled for Monday, March 16th, at 8:00 AM ET NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) --...
- 6y agoSTMLStemline Therapeutics to Host Conference Call on Fourth Quarter 2019 Financial Results on March 16, 2020GlobeNewswireNEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
- 6y agoSTMLStemline Therapeutics to Present at the Cowen 40th Annual Health Care ConferenceGlobeNewswireNEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
- 6y agoSTMLStemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth DriversGlobeNewswireNEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
- 6y agoSTMLStemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireNEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
- 6y agoSTMLStemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual MeetingGlobeNewswireNEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
- 6y agoSTMLStemline Therapeutics Names Robert M. Francomano Chief Commercial OfficerGlobeNewswireNEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
- 6y agoSTMLStemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH MeetingGlobeNewswireNEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
- 6y agoSTMLStemline Therapeutics to Present at Piper Jaffray’s 31st Annual Healthcare ConferenceGlobeNewswireNEW YORK, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
- 7y agoSTMLStemline Therapeutics Reports Third Quarter 2019 Financial ResultsGlobeNewswireNet revenue for ELZONRIS® was $13.3 million for the third quarterNew patient starts estimated to have increased greater than 20% from last quarterConference call and live webcast scheduled for...
- 7y agoSTMLStemline Therapeutics Announces Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH MeetingGlobeNewswireNEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
- 7y agoSTMLStemline Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results on November 8, 2019GlobeNewswireNEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
- 7y agoSTMLStemline Therapeutics Announces ELZONRIS® Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Japanese Society of HematologyGlobeNewswireNEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
- 7y agoSTMLStemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 CongressGlobeNewswireNEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
- 7y agoSTMLStemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 CongressGlobeNewswireNEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
- 7y agoSTMLStemline Therapeutics to Present at the 2019 Cantor Global Healthcare ConferenceGlobeNewswireNEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
- 7y agoSTMLStemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare ConferenceGlobeNewswireNEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
- 7y agoSTMLStemline Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment ConferenceGlobeNewswireNEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
- 7y agoSTMLStemline Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare ConferenceGlobeNewswireNEW YORK, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
- 7y agoSTMLStemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common StockGlobeNewswireNEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing...
- 7y agoSTMLStemline Therapeutics, Inc. (STML) CEO Ivan Bergstein on Q2 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
- 7y agoSTMLStemline Therapeutics' (STML) CEO Ivan Bergstein on Q1 2019 Results - Earnings Call TranscriptEarnings Call Transcripts